Pharma industry’s deal value decreases by 74.8 per cent in September 2022
Venture capital investments decreased by 45.8 per cent in September 2022, compared to September 2021
The pharma industry reported 81 deals worth $7.4 billion as compared to the last 12-month average (September 2021 to August 2022) of 75 deals worth $12.3 billion, the latest report from GlobalData has said.
It also said that AmerisourceBergen Corp to acquire PharmaLex Holding GmbH for $1.3 billion; Novo Nordisk AS to acquire Forma Therapeutics Holdings Inc for an equity value of $1.1 billion; Apollomics to merge with Maxpro Capital Acquisition Corp at a pre-money equity value of $899 million were the three major deals that contributed 45 per cent of the total deal value during September 2022.
Further, the report mentioned that the Venture Capital (VC) investments decreased by 45.8 per cent in September 2022, compared to September 2021. The industry reported 145 VC deals worth $2.6 billion in September 2022, compared to the last 12-month average (September 2021 to August 2022) of 154 deals worth $3.8 billion.
Acelyrin Inc raising $300 million in Series C financing to accelerate phase-III development of Izokibep; Arsenal Biosciences raising $220 million in Series B financing to advance programmable cell therapy programmes into clinical development; and RayzeBio raising $160 million in Series D financing to advance targetted radiopharmaceuticals for cancer, were the major VC deals reported in September 2022, the report concluded.